Large Elmiron Jury Awards Could Swell The Number Of Plaintiffs

Elmiron vision damage lawsuits are proceeding quietly but could get publicity if juries award large punitive damages

Friday, August 13, 2021 - Courts are rapidly moving toward the first Elmiron vision damage trials slated to begin in January of 2023. This would be a little over three years from the December 20, 2020 date that the U.S. Judicial Panel on Multidistrict Litigation (JPML) ordered cases into multidistrict litigation (MDL). The purpose of MDL is to save countless hours of court time by not performing repetitive procedures. Experts will be interviewed to get their take on whether or not Elimron causes maculopathy and macular degeneration. The judge is in the process of developing several cases to be tried as bellwether cases. The jury's reaction to the evidence will weigh heavily as to whether or not a settlement can be reached. Settling the cases will further save court time. If not, the remainder of the cases will go before juries individually, one by one. MDL is not a class action as each case is heard and stands on its own merits. Elmiron vision lawsuits have been quietly filed by about 250 plaintiffs out of the millions of women that are taking Elmiron. Plaintiff attorneys think that there is the potential for significant monetary awards to be paid to the first plaintiffs in the bellwether proceedings. There is still time to file an Elmiron vision damage lawsuit. Elmiron vision damage attorneys may work on a contingency basis and may take your case without you having to pay them initially. A fee is charged only if a favorable outcome is achieved.

Several items of contention surround the lack of an adequate Elmiron eyesight damage warning. Most importantly, the US Food and Drug Administration (FDA) delayed for over two decades before telling Janssen Pharmaceutical to update its Elmiron night blindness vision damage warnings to include the probability of developing macular degeneration. The warnings also parallel those that tell patients that Elmiron vision damage is progressive and will continue to worsen in perpetuity even if they stop taking the drug. Elmiron is not like aspirin even though it is taken to reduce pain. Elmiron is an anti-viral drug that must be taken for about three months before it accumulates sufficiently in the blood cells to becomes effective. According to the Food and Drug Administration (FDA), "Elmiron is not a pain medication like aspirin or acetaminophen and therefore must be taken continuously for relief as prescribed." Ironically, studies have shown that taking Elmiron helps less than one-third of those who use it and most of the pain relief may be due to the placebo effect. Another interesting fact is that until Elmiron was suspected to cause vision damage, most patients were diagnosed as having age-related maculopathy. From what scientists know today, hundreds of thousands of women who can not drive at night nor read in less than optimal lighting conditions may have avoided their night blindness condition had they not taken Elmiron. For the record, Elmiron is prescribed to alleviate interstitial cystitis (IC) also known as painful bladder syndrome, usually occurring after a woman has given birth.

More Recent Elmiron Eye Lawsuit News:

Lawyers for Elmiron Eye Lawsuits

Attorneys handling Elmiron Eye lawsuits for leukemia, non-Hodgkin lymphoma, and multiple myeloma offer free, no-obligation case review for individuals and families who believe they may have grounds to file a Elmiron Eye lawsuit. Working on a contingency basis, these attorneys are committed to never charging legal fees unless they win compensation in your Elmiron Eye lawsuit. The product liability litigators handling Roundup claims at OnderLaw have a strong track record of success in representing families harmed by dangerous drugs and consumer products.